ZBH250117P70000
- 0.05
- 0.000.00%
Zimmer Biomet Holdings Newsroom
Bernstein Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Cuts Target Price to $111
Bernstein Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Cuts Target Price to $122
Bernstein Reaffirms Their Hold Rating on Zimmer Biomet Holdings (ZBH)
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $130
Zimmer Biomet Holdings (ZBH) Receives a Buy From RBC Capital
Evercore Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $113
Zimmer Biomet Holdings (ZBH) Gets a Hold From Wells Fargo
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $130
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $118
Bernstein Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $133
Zimmer Biomet Holdings Analyst Ratings
J.P. Morgan Upgrades Zimmer Biomet Holdings(ZBH.US) to Buy Rating, Raises Target Price to $128
Zimmer Biomet Holdings Analyst Ratings
Barclays Cuts Zimmer Biomet Price Target to $118 From $125, Maintains Underweight Rating
Citi Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $120
Morgan Stanley Initiates Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $115
Wells Fargo Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Hold Rating for Zimmer Biomet Holdings Amid Uncertain Impact of New Product Launch in US Market
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Zimmer Biomet Holdings Is Maintained at Outperform by RBC Capital